Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation
Observational study in the routine clinical practice setting to evaluate the short and long
term safety profile of Radium-223 in metastatic castration resistant prostate cancer
patients and to evaluate the risk of developing second primary cancers.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society